Xenon Pharmaceuticals Inc (XENE) financials
Xenon Pharmaceuticals revenue and earnings by year
Xenon Pharmaceuticals's revenue was $7.50 million in the fiscal year to December 31, 2025, down 20.5% from the year before. Net income was -$346 million, -4612.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 17.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 8 | 9 | 18 | 32 | 7 | 0 | 2 |
| Revenue growth | -20.5% | -48.8% | -42.7% | 371.0% | 2095.8% | -82.8% | — |
| Operating income | -373 | -129 | -79 | -31 | -43 | -33 | -25 |
| Operating margin | -4974.3% | -1368.9% | -428.4% | -97.3% | -627.0% | -10474.3% | -1376.4% |
| Net income | -346 | -125 | -79 | -29 | -42 | -31 | -23 |
| Net margin | -4612.1% | -1328.9% | -427.8% | -89.7% | -609.1% | -9872.7% | -1275.5% |
| Diluted EPS | -$4.36 | -$2.06 | -$1.77 | -$0.81 | — | -$1.72 | -$1.48 |
| Free cash flow | -280 | -104 | -72 | -51 | -6 | -29 | -20 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open XENE in Markets.
See also: XENE returns
No forecast, no recommendation. This page describes Xenon Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.